ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,650.55
0.34%
Dow Jones
40,761.60
1.37%
US Dollar vs MXN
17.68251
-0.27%
Brent Oil
83.325
-1.20%
Bitcoin
64,531.66
-0.49%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Acceleron Pharma Inc (XLRN)

  7. Acceleron Pharma Inc (XLRN) Noticias

XLRN

Acceleron Pharma (XLRN)

Acceleron Pharma Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:XLRN
FechaHoraFuenteTítuloSímboloCompañía
09/09/201906:00Business WireAcceleron Receives FDA Orphan Drug Designation for Sotatercept in Pulmonary Arterial HypertensionNASDAQ:XLRNAcceleron Pharma Inc
12/08/201915:19Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XLRNAcceleron Pharma Inc
05/08/201915:13Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:XLRNAcceleron Pharma Inc
05/08/201915:09Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:XLRNAcceleron Pharma Inc
05/08/201915:05Business WireAcceleron Reports Second Quarter 2019 Operating and Financial ResultsNASDAQ:XLRNAcceleron Pharma Inc
24/07/201906:00Business WireAcceleron to Webcast Second Quarter 2019 Operating and Financial Results on August 5, 2019NASDAQ:XLRNAcceleron Pharma Inc
05/07/201908:54Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:XLRNAcceleron Pharma Inc
26/06/201906:35Business WireAcceleron Completes Target Enrollment in the PULSAR Phase 2 Trial of Sotatercept in Pulmonary Arterial HypertensionNASDAQ:XLRNAcceleron Pharma Inc
10/06/201906:00Business WireAcceleron Announces Retirement of Director and Co-Founder Tom ManiatisNASDAQ:XLRNAcceleron Pharma Inc
07/06/201915:39Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:XLRNAcceleron Pharma Inc
04/06/201907:24Dow Jones NewsFDA Accepts Celgene, Acceleron BLA for Anemia Drug LuspaterceptNASDAQ:XLRNAcceleron Pharma Inc
04/06/201906:30Business WireCelgene Corp. & Acceleron Pharma Announce U.S. FDA Accepts Luspatercept Biologics License Application in Myelodysplastic Synd...NASDAQ:XLRNAcceleron Pharma Inc
14/05/201906:00Business WireAcceleron to Present at the UBS Global Healthcare ConferenceNASDAQ:XLRNAcceleron Pharma Inc
09/05/201915:05Business WireAcceleron Reports First Quarter 2019 Operating and Financial ResultsNASDAQ:XLRNAcceleron Pharma Inc
01/05/201906:00Business WireAcceleron to Webcast First Quarter 2019 Operating and Financial Results on May 9, 2019NASDAQ:XLRNAcceleron Pharma Inc
26/04/201906:30Business WireCelgene Corp. & Acceleron Pharma Announce Submission of Luspatercept Marketing Authorization Application to the European Medi...NASDAQ:XLRNAcceleron Pharma Inc
12/04/201915:23Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:XLRNAcceleron Pharma Inc
12/04/201915:21Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:XLRNAcceleron Pharma Inc
05/04/201915:01Business WireAcceleron Announces Departure of Chief Medical OfficerNASDAQ:XLRNAcceleron Pharma Inc
05/04/201909:24Dow Jones NewsCelgene Files BLA for Anemia Drug Luspatercept With FDANASDAQ:XLRNAcceleron Pharma Inc
05/04/201908:28Business WireCelgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Biologics License Application to U.S. FDANASDAQ:XLRNAcceleron Pharma Inc
04/04/201915:05Business WireAcceleron Discontinues Development of Phase 1 Molecule ACE-2494NASDAQ:XLRNAcceleron Pharma Inc
05/03/201906:00Business WireAcceleron Receives FDA Orphan Drug Designation for ACE-083 in Charcot-Marie-Tooth DiseaseNASDAQ:XLRNAcceleron Pharma Inc
27/02/201915:31Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:XLRNAcceleron Pharma Inc
27/02/201915:22Edgar (US Regulatory)Annual Report (10-k)NASDAQ:XLRNAcceleron Pharma Inc
27/02/201915:05Business WireAcceleron Reports Fourth Quarter and Full Year 2018 Operating and Financial ResultsNASDAQ:XLRNAcceleron Pharma Inc
26/02/201907:54Dow Jones NewsCelgene to File Luspatercept BLA With FDA in AprilNASDAQ:XLRNAcceleron Pharma Inc
19/02/201906:00Business WireAcceleron to Webcast Fourth Quarter and Full Year 2018 Operating and Financial Results on February 27, 2019NASDAQ:XLRNAcceleron Pharma Inc
14/02/201913:07Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:XLRNAcceleron Pharma Inc
13/02/201906:00Business WireAcceleron to Present at Two Upcoming Healthcare Investor ConferencesNASDAQ:XLRNAcceleron Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:XLRN

Su Consulta Reciente

LSE
ORI
Oriel Resources
NYSE
BWA
BorgWarner
LSE
ARS
Asiamet Resources
LSE
KMR
Kenmare Resources
NASDAQ
BYND
Beyond Meat
BIT
XLPS
Invesco Consumer Staples...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados